RNF39 Inhibitors
RNF39 inhibitors primarily focus on modulating the broader ubiquitin-proteasome system (UPS). MG132 and Lactacystin, for instance, directly inhibit the proteasome, halting the degradation of ubiquitinated proteins. Such inhibitors can indirectly influence the function or activity of RNF39 by saturating or disrupting the ubiquitin pathway. Additionally, by targeting upstream enzymes in the ubiquitination cascade, like the E1 enzyme inhibitor PYR-41, the ubiquitination of substrates can be hindered, which can subsequently influence proteins like RNF39 that might be involved in these processes.
Furthermore, deubiquitinase inhibitors, such as P22077 or IU1, have a pivotal role in regulating ubiquitin dynamics. The neddylation inhibitor, MLN4924, and the MDM2 antagonist, Nutlin-3, offer alternative methods of affecting the UPS and, in turn, RNF39's role in this system. Finally, compounds like Thalidomide highlight the broader approach of targeting specific ubiquitin ligase complexes, suggesting a way in which RNF39's activity might be indirectly altered by changing the cellular ubiquitination landscape.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor which can block the degradation of ubiquitinated proteins. This may indirectly influence RNF39's ubiquitin-related activities. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor; by blocking proteasomal degradation, it can affect the ubiquitin-proteasome system and potentially RNF39's function. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Ubiquitin-activating enzyme (E1) inhibitor. By blocking the initial step of ubiquitination, RNF39's ubiquitin ligase activity can be affected. | ||||||
P22077 | 1247819-59-5 | sc-478536 | 10 mg | $165.00 | ||
USP7-specific deubiquitinase inhibitor. Modulates ubiquitin dynamics and can indirectly influence RNF39's ubiquitin-related activities. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
NEDD8-activating enzyme inhibitor, affects neddylation and thereby influences the ubiquitin-proteasome system and potentially RNF39's function. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
Inhibits proteasome-associated deubiquitinase USP14. This can affect ubiquitin dynamics and potentially influence RNF39's activities. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 antagonist. Given MDM2's role in ubiquitination, this can indirectly affect ubiquitin ligase activity and potentially RNF39's function. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
Broad-spectrum deubiquitinase inhibitor. By influencing deubiquitination, it may affect RNF39's ubiquitin-related functions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, can affect ubiquitin-proteasome system dynamics, potentially influencing RNF39's function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Targets cereblon, a component of a ubiquitin ligase complex. Can potentially influence other ubiquitin ligases, including RNF39. | ||||||